Oncoclínicas do Brasil Serviços Médicos Past Earnings Performance
Past criteria checks 5/6
Oncoclínicas do Brasil Serviços Médicos has been growing earnings at an average annual rate of 54.6%, while the Healthcare industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 28.9% per year. Oncoclínicas do Brasil Serviços Médicos's return on equity is 11.7%, and it has net margins of 4.1%.
Key information
54.6%
Earnings growth rate
51.0%
EPS growth rate
| Healthcare Industry Growth | 11.6% |
| Revenue growth rate | 28.9% |
| Return on equity | 11.7% |
| Net Margin | 4.1% |
| Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Apr 17
Oncoclínicas do Brasil Serviços Médicos' (BVMF:ONCO3) Earnings Are Weaker Than They Seem
Apr 03Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) Has A Somewhat Strained Balance Sheet
Mar 11What Does Oncoclínicas do Brasil Serviços Médicos S.A.'s (BVMF:ONCO3) Share Price Indicate?
Feb 17It's A Story Of Risk Vs Reward With Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3)
Dec 08Why Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Could Be Worth Watching
Nov 06Is Now The Time To Put Oncoclínicas do Brasil Serviços Médicos (BVMF:ONCO3) On Your Watchlist?
Sep 11Oncoclínicas do Brasil Serviços Médicos S.A. (BVMF:ONCO3) Just Reported Earnings, And Analysts Cut Their Target Price
Apr 03Revenue & Expenses BreakdownBeta
How Oncoclínicas do Brasil Serviços Médicos makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,489 | 224 | 1,172 | 0 |
| 30 Sep 23 | 5,271 | 219 | 1,123 | 0 |
| 30 Jun 23 | 5,033 | 145 | 1,092 | 0 |
| 31 Mar 23 | 4,574 | 91 | 1,052 | 0 |
| 31 Dec 22 | 4,088 | 46 | 981 | 0 |
| 30 Sep 22 | 3,640 | -10 | 920 | 0 |
| 30 Jun 22 | 3,155 | 105 | 661 | 0 |
| 31 Mar 22 | 2,895 | -67 | 749 | 0 |
| 31 Dec 21 | 2,702 | -47 | 688 | 0 |
| 30 Sep 21 | 2,509 | -203 | 742 | 0 |
| 30 Jun 21 | 2,354 | -334 | 836 | 0 |
| 31 Mar 21 | 2,182 | -145 | 622 | 0 |
| 31 Dec 20 | 2,035 | -158 | 604 | 0 |
| 31 Dec 19 | 1,690 | -20 | 483 | 0 |
| 31 Dec 18 | 1,051 | -17 | 317 | 0 |
| 31 Dec 17 | 792 | 3 | 227 | 0 |
| 31 Dec 16 | 595 | -25 | 180 | 0 |
| 31 Dec 15 | 458 | -25 | 135 | 0 |
| 31 Dec 14 | 359 | -22 | 114 | 0 |
| 31 Dec 13 | 269 | 21 | 60 | 0 |
Quality Earnings: ONCO3 has high quality earnings.
Growing Profit Margin: ONCO3's current net profit margins (4.1%) are higher than last year (1.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONCO3 has become profitable over the past 5 years, growing earnings by 54.6% per year.
Accelerating Growth: ONCO3's earnings growth over the past year (383.4%) exceeds its 5-year average (54.6% per year).
Earnings vs Industry: ONCO3 earnings growth over the past year (383.4%) exceeded the Healthcare industry 38.6%.
Return on Equity
High ROE: ONCO3's Return on Equity (11.7%) is considered low.